Curocell's Rimcato Covered by Health Insurance from December; Per-Dose Price at 280 Million Won
For patients with relapsed or refractory DLBCL
Also pursuing a second-line treatment indication
Starting December 1, South Korea's first domestically developed chimeric antigen receptor T-cell (CAR-T) therapy, Rimcato, will be covered by national health insurance.
Curocell announced on November 20 that the reimbursement ceiling per dose of Rimcato has been set at 280,016,050 won.
A view of Curocell's Daejeon headquarters (research institute) and GMP plant. Curocell
View original imageWith the coverage taking effect, adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) will be able to receive Rimcato treatment with national health insurance benefits.
Curocell is also pursuing an expansion of Rimcato's indications. Last month, it applied for approval of an amendment to its investigational new drug (IND) plan for a Phase 3 clinical trial to secure a second-line treatment indication for relapsed or refractory diffuse large B-cell lymphoma. It aims to begin the Phase 3 trial in the first half of next year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
"With Rimcato now covered by national health insurance, we can offer a real treatment opportunity to patients who had to hesitate because of the cost," Curocell CEO Kim Geonsu said. "We will work closely with medical institutions and ensure the supply system runs smoothly so patients can receive treatment promptly and reliably."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.